An example is a 21-gene RT-PCR-based test, which interrogates tumor RNA to predict recurrence risk and magnitude of chemotherapy benefit in early estrogen receptor positive (ER+) breast cancer [4], [8]–[10]. This evidence concerns the gene ESR1 and breast carcinoma.